Marburg, Germany: Decontamination chambers, tight-fitting protective suits, a controlled atmosphere: vigilance is the order of the day when making Covid-19 vaccines at the new BioNTech plant in Marburg, Germany.
The above quote from Germany’s BioNtech mRNA vaccine manufacturer was informing you just how dangerous COVID-19 vaccines are. If the mRNA vaccines were safe why were BioNTech labs equipped with decontamination chambers and why were Germany’s lab technicians wearing full hazmat suits? The CDC noted that none of the vaccines use the live virus that causes COVID-19. So why use biological weapons handling precautions to make COVID-19 mRNA vaccines? Because BioNtech’s mRNA vaccines are bioweapons. The ingredients that were used to make Germany’s mRNA vaccines could and did in fact trigger/cause other harmful and deadly diseases and virus mutations/variants.
An antigen is a thing that can provoke an immune response. In the case of vaccines, antigens are usually parts of the pathogens (infectious microorganisms) that cause disease. Some vaccines may have multiple antigens in a single shot. Some vaccines are based on the toxin produced by the pathogen that causes the disease symptoms. Germany’s COVID-19 mRNA vaccines contained the unique protein that gives COVID-19 its specific characteristics like spread and virulence – the human herpes virus ORF10 protein.
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019-20 coronavirus outbreak. SARS-CoV-2 virus proteins include structural proteins, non-structural proteins and accessory factors. The structure of SARS-CoV-2 consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. SARS-CoV-2 non-structural protein is ORF1ab that consists of 16 proteins (nsp1-nsp16), while accessory factors include ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, and ORF10
SARS-CoV-2 (COVID-19) ORF10 antibody is supplied to vaccine research and development labs in PBS containing 0.02 % sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE. Quote by the CDC:
When Sodium azide is mixed with water or an acid it changes rapidly to a toxic gas with a sharp odor as well as releasing hydrazoic acid (HN3) .. Exposure to sodium azide can be fatal.
GENERAL INFORMATION: First Responders should use a NIOSH-certified Chemical, Biological, Radiological, Nuclear (CBRN) Self Contained Breathing Apparatus (SCBA) with a Level A protective suit when entering an area with an unknown contaminant or when entering an area where the concentration of the contaminant is unknown.
UN 2019 Biological Weapons Convention states:
“Biological weapons disseminate disease-causing organisms or toxins to harm or kill humans, animals or plants. They can be deadly and highly contagious. … The consequences of the deliberate release of biological agents or toxins by state or non-state actors could be dramatic.”
COVID-19 was/is a Germany and the WHO planned and lead bioterrorism/biological attack. The initial SARS-CoV-2 outbreak (epidemic) quickly ended/died out by the end of January 2020 as reported by the WHO which publicly stated:
“that the SARS-CoV-2 epidemic in China peaked and plateaued between 23 January and 2 February 2020, and had been declining steadily since then” CNBC report.
So an act of COVID-19 bioterrorism was perpetrated by Germany, the WHO, and Germany’s proxy, the World Economic Forum to coerce the World leaders to invest in/buy Germany’s ORF10 viral protein laced mRNA vaccines.
“It’s an amazing start to what’s going to be a huge year for worldwide support of vaccinations.” Global Citizen January 31, 2020 (Brexit Day) at the World Economic Forum regarding Germany sponsoring/funding the COVID-19 bioterrorism attack.
Germany’s COVID-19 mRNA vaccines were manufactured and disseminated as a bioweapon – “to harm or kill humans”. Germany and the UN (the WHO) aimed to profit from COVID-19. Germany began developing mRNA vaccines and conducted mRNA vaccines clinical trials prior to start of the COVID-19 bioterrorism attack.
“As personalized mRNA vaccines go through trials, Moderna, BioNTech and CureVac, based in Tübingen, Germany, are simultaneously developing off-the-shelf vaccine candidates ” Injection of Hope
The Marburg plant where Germany manufactured BioNtech’s mRNA vaccines was formerly owned by Swiss pharmaceutical group Novartis – an assignee of the 2003 patent for the lab created novel SARS-CoV-2 coronavirus.
Screenshot of September 2020 Reuters report:
Patent US-2006257852-A1 specifically names the ORF10 protein – a protein that is exclusively found in SARS-CoV-2 genome and not in SARS-CoV, being used/encoded in the fusion protein of the patented novel SARS coronavirus:
“The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc.“
“Accordingly, the invention further includes a SARS virus subunit vaccine comprising a fusion protein. Preferably, the fusion protein comprises a first amino acid sequence encoded by a SARS virus polynucleotide sequence. SARS virus polynucleotide sequences which may encode said first amino acid sequence include one or more of the SARS virus polynucleotide sequences identified in this application and fragments thereof. “
Germany’s BioNtech disclosed in SEC filing that its COVID-19 vaccines are dangerous – may cause death:
Our product candidates may not work as intended, may cause undesirable side effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences.
… use of our product candidates (Pfizer-BioNTech COVID-19 vaccine) could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. The potential for adverse events is especially acute in the oncology setting, where patients may have advanced disease, have compromised immune and other systems and be receiving numerous other therapies.